Expectations trend
FY2028 · fiscal year ending 2028-05-31 · alphavantage
CHRONOSCALE CORPORATION (CHRN)
NASDAQIndustrialsInformation Technology ServicesSnapshot 2026-11-04
$10.16-15.68%
Close 2026-11-05 · 1-day change
NASDAQIndustrialsInformation Technology ServicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Oct 4, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for CHRN yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Achieve $1 billion annualized revenue run rate | It targets $1 billion in annualized revenue by Q3 2027. | Improving | fails to secure contracts to support $1 billion revenue by Q3 2027 | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “|| ● | Announced a contract extension with an existing AI customer and a new customer agreement, putting ChronoScale on track for $1 billion in annualized run-rate revenue* by calendar Q3 2027.” “Financial Results from Operations for Fiscal First Quarter 2027 Revenue in the fiscal first quarter of 2027 was $41.5 million, up 148% from $16.7 million in the fiscal first quarter of 2026.” Revenue was $41.482 million in 2027-Q1. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-05-31 · alphavantage
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative growth business, not yet a proven durable compounder, because revenue is growing quickly while the company remains loss-making. The multi-year view is on watch: recent momentum and quality measures improved, but an earnings miss and leadership transitions keep execution uncertain.
CHRN is expensive versus peers, and the valuation depends in part on future opportunity rather than established profits. The evidence flags an expectations gap, but confidence in that measure is low; the valuation is not described as part of a broader fragile mix of expensive, weak, and turbulent conditions.
Near term, miss risk is elevated, and recent results have been weak relative to the industry group. Fiscal Q1 2027 revenue grew sharply, but the continuing-operations loss shows profitability progress is not yet established; the company has completed the Ekso sale and shifted focus toward cloud operations. Management’s larger revenue milestone is still prospective, and delivery of the planned Microsoft deployment is not demonstrated in the supplied evidence.
The multi-year thesis hinges on scaling AI infrastructure alongside customer demand and converting revenue growth into better financial performance. Near term, another guidance cut or continued earnings misses would weaken the setup; continued strength from industrial bellwethers could support the sector backdrop, while misses or lower guidance could remove that support.
Over the next 1 to 3 years, CHRN offers substantial growth potential but has not yet shown that growth can deliver profitability, and execution remains uncertain. The thesis stays on watch, with the next results and progress on planned deployments as key tests. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Secure $100 million in capital through financing | A supporting condition in CHRONOSCALE CORPORATION's published investment case. The stated target is 100.0. | Intact | fails to secure $100 million in financing | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Maintain gross margins between 52% and 53% | Gross margins are expected to be between 52% and 53%. | Broken | gross margin falls below 52% | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Oct 4, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.73 → $0.17 · observed estimates
$1.46B → $0.95B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-09-22 | $-1.73 | $1,458,200,000 | 1 / 1 |
| 2026-09-24 | $-1.73 | $1,458,200,000 | 1 / 1 |
| 2026-09-25 | $-1.73 | $1,458,200,000 | 1 / 1 |
| 2026-09-26 | $-1.73 | $1,458,200,000 | 1 / 1 |
| 2026-09-27 | $-1.73 | $1,458,200,000 | 1 / 1 |
| 2026-09-28 | $-1.73 | $1,458,200,000 | 1 / 1 |
| 2026-09-29 | $-1.73 | $1,458,200,000 | 1 / 1 |
| 2026-09-30 | $-1.73 | $1,458,200,000 | 1 / 1 |
| 2026-10-01 | $-1.73 | $1,458,200,000 | 1 / 1 |
| 2026-10-02 | $-1.73 | $1,458,200,000 | 1 / 1 |
| 2026-10-03 | $-1.73 | $1,458,200,000 | 1 / 1 |
| 2026-10-04 | $-1.73 | $1,458,200,000 | 1 / 1 |
| 2026-10-05 | $-1.73 | $1,458,200,000 | 1 / 1 |
| 2026-10-06 | $-0.22 | $930,200,000 | 1 / 1 |
| 2026-10-07 | $-0.22 | $930,200,000 | 1 / 1 |
| 2026-10-08 | $-0.22 | $930,200,000 | 1 / 1 |
| 2026-10-09 | $-0.22 | $930,200,000 | 1 / 1 |
| 2026-10-10 | $-0.22 | $930,200,000 | 1 / 1 |
| 2026-10-11 | $-0.22 | $930,200,000 | 1 / 1 |
| 2026-10-12 | $-0.22 | $930,200,000 | 1 / 1 |
| 2026-10-13 | $-0.22 | $930,200,000 | 1 / 1 |
| 2026-10-14 | $-0.22 | $930,200,000 | 1 / 1 |
| 2026-10-15 | $-0.22 | $930,200,000 | 1 / 1 |
| 2026-10-16 | $-0.22 | $930,200,000 | 1 / 1 |
| 2026-10-17 | $-0.22 | $930,200,000 | 1 / 1 |
| 2026-10-18 | $-0.22 | $930,200,000 | 1 / 1 |
| 2026-10-19 | $-0.22 | $930,200,000 | 1 / 1 |
| 2026-10-20 | $-0.22 | $930,200,000 | 1 / 1 |
| 2026-10-21 | $-0.22 | $930,200,000 | 1 / 1 |
| 2026-10-22 | $-0.22 | $930,200,000 | 1 / 1 |
| 2026-10-23 | $-0.22 | $930,200,000 | 1 / 1 |
| 2026-10-24 | $0.17 | $947,750,000 | 2 / 2 |
| 2026-10-25 | $0.17 | $947,750,000 | 2 / 2 |
| 2026-10-26 | $0.17 | $947,750,000 | 2 / 2 |
| 2026-10-27 | $0.17 | $947,750,000 | 2 / 2 |
| 2026-10-28 | $0.17 | $947,750,000 | 2 / 2 |
| 2026-10-29 | $0.17 | $947,750,000 | 2 / 2 |
| 2026-10-30 | $0.17 | $947,750,000 | 2 / 2 |
| 2026-10-31 | $0.17 | $947,750,000 | 2 / 2 |
| 2026-11-01 | $0.17 | $947,750,000 | 2 / 2 |
| 2026-11-02 | $0.17 | $947,750,000 | 2 / 2 |
| 2026-11-03 | $0.17 | $947,750,000 | 2 / 2 |
| 2026-11-04 | $0.17 | $947,750,000 | 2 / 2 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.